Emerging Research Links Ozempic and Other GLP-1 Drugs to Serious Vision Loss (NAION)

Since 2024, a growing body of scientific research has examined whether GLP-1 receptor agonists—including semaglutide (Ozempic and Wegovy)—are associated with non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and potentially permanent form of optic-nerve damage.

NAION is a medical emergency that can cause abrupt vision loss, often upon waking, and may result in irreversible blindness in one or both eyes.

Our Role

We represent individuals who developed NAION or sudden vision loss after using Ozempic or other GLP-1 medications. Our firm is closely monitoring both the New Jersey state Multicounty Litigation (MCL) and the federal NAION MDL, and we expect to take an active role in developing and prosecuting the New Jersey litigation.

What the Published Studies Show

2024: First Large-Scale Study Identifies a Risk Signal

In 2024, researchers published a matched cohort study in JAMA Ophthalmology analyzing large healthcare databases. The study reported that patients prescribed semaglutide had a higher observed risk of developing NAION compared with matched patients treated with non-GLP-1 comparator medications for diabetes or obesity.¹

The authors emphasized that typical limitations of observational research mean the study cannot by itself prove causation, even though the association was statistically significant.¹

2025: Additional Analyses Expand the Evidence Base

Subsequent analyses through 2025 have continued to evaluate the potential link:

• A 2025 cohort analysis in JAMA Ophthalmology examined semaglutide exposure and NAION using distinct methods and patient populations, reflecting the ongoing effort to replicate and refine the initial findings.²
• An FDA Sentinel Initiative analysis (September 2025) evaluated NAION risk after GLP-1 receptor agonist exposure using large administrative claims data. Such Sentinel analyses are part of the FDA’s established post-marketing safety surveillance infrastructure.³
• A September 2025 medRxiv preprint using Veterans Health Administration data applied a “target-trial emulation” approach and reported an elevated NAION risk signal among semaglutide initiators relative to certain comparators. Because this is a preprint, it should be interpreted as preliminary pending peer review and formal publication.⁴

This is an actively developing scientific topic and, considering the popularity of GLP-1 drugs, is likely to continue to be a matter of significant interest to the medical and scientific community.

What Medical Institutions Are Saying

Following the 2024 research, the Mass Eye and Ear (Harvard-affiliated) press office issued a public release that explained the study findings and why NAION is a serious clinical event requiring prompt evaluation.⁵

The American Academy of Ophthalmology (AAO) also summarized the research for patients and clinicians, emphasizing that sudden vision loss of any kind demands immediate medical evaluation, irrespective of cause.⁶

What Is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood flow to the optic nerve is interrupted or insufficient. Unlike many other eye diseases, NAION typically presents suddenly, often without warning.

Common symptoms include:
• Sudden vision loss in one eye (sometimes both)
• Vision loss noticed upon waking
• Blurred or dim vision
• Dark or missing areas in the visual field
• Reduced color or contrast perception

Vision loss from NAION is frequently permanent. There is currently no proven treatment to reverse the optic-nerve damage once it occurs.

Why This Matters Now

GLP-1 drugs such as Ozempic and Wegovy are prescribed to millions of patients, including many without diabetes. As use has expanded, researchers and regulators have broadened post-marketing safety evaluations to include conditions not fully recognized during pre-approval trials, such as optic-nerve injury.

If you or a loved one experienced sudden vision changes or optic-nerve damage after taking a GLP-1 drug, we encourage you to contact us for a confidential consultation.

Citations

1. Hathaway et al., “Association of Semaglutide Use With Non-Arteritic Anterior Ischemic Optic Neuropathy” JAMA Ophthalmology (2024). Available at jamanetwork.com.
2. JAMA Ophthalmology (2025 cohort analysis). Available at jamanetwork.com.
3. FDA Sentinel Initiative, Risk of NAION Following GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus, Version 3.0 (Sep. 2, 2025). Available at sentinelinitiative.org.
4. medRxiv preprint (Sep. 18, 2025): “Target Trial Emulation of Semaglutide and NAION Risk” (pre-peer review). Available at medrxiv.org.
5. Mass Eye and Ear news release (July 2024), “Prescription Weight-Loss Drugs Linked to Blinding Condition.” Available at masseyeandear.org.
6. American Academy of Ophthalmology, “Weight-Loss Drug and Eye Health” (July 2024). Available at aao.org.